2024-10-07 - Analysis Report
## AbbVie Inc. (ABBV) Stock Analysis Report

**Company Overview:** AbbVie Inc. is a global pharmaceutical company that develops, manufactures, and markets a wide range of prescription drugs.

**Performance Analysis:**

**1. Performance Relative to S&P 500 (VOO):**

* **Cumulative Return:** ABBV has a cumulative return of 152.53% compared to 133.14% for the S&P 500 (VOO).
* **Deviation:** ABBV currently outperforms VOO by 19.39%,  which places it at the 60.63% percentile of historical performance relative to VOO.

**2. Recent Price Action:**

* **Closing Price:** 194.29
* **5-Day Moving Average:** 196.2
* **20-Day Moving Average:** 194.72
* **60-Day Moving Average:** 189.8

**3. Technical Indicators:**

* **RSI:** 45.85 – Suggests the stock is neither overbought nor oversold.
* **PPO:** -0.06 – Indicates a slight bearish momentum.
* **Delta_Previous_Relative_Divergence:** -11.18 – Shows a recent decline in relative performance compared to VOO, suggesting potential downward pressure.
* **Expected Return:** 0.99% – Indicates a maximum potential 5-year expected return based on current investment, exceeding VOO's expected return.

**4. Recent Earnings and Outlook:**

| Date | EPS | Expected EPS |
|---|---|---|
| 2024-07-25 | 2.65 | 2.57 |
| 2024-04-26 | 2.31 | 2.26 |
| 2024-02-02 | 2.79 | 2.76 |
| 2023-10-27 | 2.95 | 2.86 |
| 2023-07-27 | 2.91 | 2.79 |

* **Recent Earnings:** ABBV exceeded analysts' expectations for the quarter ending July 25th, 2024, with an EPS of 2.65 compared to the expected 2.57. 
* **Outlook:** AbbVie's recent earnings performance is positive, demonstrating consistent outperformance against analysts' estimates. This bodes well for the company's future performance, though it's important to note that this is a single quarter and long-term outlook may be affected by factors such as regulatory changes and competitive landscape.

**5. News and Recent Developments:**

* **Recent Market Outlook:** AbbVie has been a steady performer, offering a relatively low-risk investment opportunity for investors seeking a dividend-paying pharmaceutical stock. However, some analysts are concerned about the potential decline of Humira's market share. 
* **Analyst Opinions:** While some analysts are optimistic about the long-term prospects of AbbVie, others are cautious about the company's dependence on Humira. 
* **Performance Highlights:** AbbVie has consistently delivered strong earnings and exceeded analysts' expectations. The company's strong R&D pipeline and focus on developing innovative therapies for chronic diseases are key drivers of its growth potential. 

**6. Summary and Conclusion:**

Overall, ABBV appears to be a relatively stable and predictable investment with a track record of exceeding S&P 500 performance. The company's solid earnings, strong R&D pipeline, and dividend-paying strategy make it an attractive option for long-term investors. However, the potential decline of Humira's market share is a key risk to consider. Investors should closely monitor the company's performance, news, and analyst opinions before making any investment decisions. 
